News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediGene, Inc. To Present At The Biotechnology Industry Organization (BIO) CEO & Investor Conference In New York


10/19/2005 5:12:44 PM

MARTINSRIED and MUNICH, Germany and SAN DIEGO, Feb. 15 /PRNewswire- FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) [MDGGn.DE] announced today that the company will be presenting at the BIO CEO & Investor Conference in New York, on February 24, at 3.00 p.m. local time, at the Waldorf Astoria Hotel. Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, will give a review of the company and update the audience on current clinical and business developments. The presentation will be available on the internet at http://www.medigene.com/ from February 24 on.

MediGene possesses a mature drug pipeline with a drug available on the European market (Eligard(R) for the treatment of prostate cancer) and several drug candidates, undergoing all stages in clinical development (phases I-III), such as Polyphenon(R) E Ointment for the treatment of skin tumors which has recently completed clinical phase III. In addition, MediGene owns cutting-edge platform technologies with the HSV as well as the recently acquired EndoTAG technologies. The EndoTAG drug candidates utilize the already approved and applied therapy of anti-angiogenesis (suppressing tumor vascularization), while adding another, novel mode of action: the innovative carrier system of lipid complexes allows a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause the selective attachment to and destruction of tumor blood vessels ("neovascular targeting"). The drug candidate EndoTAG-1 has already undergone several clinical phase I trials in various cancer diseases. In 2005, MediGene is planning to initiate a number of phase II trials of EndoTAG-1 in two cancer indications.

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) is a trademark of MediGene AG, Eligard(R) is a trademark of QLT USA, Inc. (formerly Atrix), Polyphenon(R) E is a trademark of Mitsui Norin.

MediGene AG

CONTACT: Dr. Michael Nettersheim, Investor Relations, +49-89-85-65-2946,or Julia Hofmann, Corporate Communications, +49-89-85-65-3324, both ofMediGene AG, investor@medigene.com, or fax, +49-89-85-65-2920


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES